Company Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada.
The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Neil K. Warma |
Contact Details
Address: 1920 Yonge Street, Suite 200 Toronto, ON M4S 3E2 Canada | |
| Phone | 416 847 6898 |
| Website | promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M4065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | Chief Executive Officer, President and Director |
| Eugene W. Williams | Co-Founder and Chairman |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer and Director |
| Gavin T. Malenfant | Chief Operating Officer |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. Ernest D. Bush Ph.D. | Head of Pharmacology/Toxicology and Senior Consultant |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dennis Chen Ph.D. | Head of Manufacturing and Senior Consultant |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2024 | 8-K | Current Report |
| Oct 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 10, 2024 | 8-K | Current Report |
| Sep 9, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 9, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 6, 2024 | EFFECT | Notice of Effectiveness |
| Sep 3, 2024 | UPLOAD | Filing |
| Aug 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Aug 8, 2024 | 10-Q | Quarterly Report |